Difficulty: Medium
Average Score: 82%
Practice
A 59-year-old man with Parkinson's disease begins a course of bromocriptine in hopes of improving his significant symptoms of cogwheel rigidity and bradykinesia. After being on the medication for 6 months, a renal ultrasound is obtained that reveals bilateral hydronephrosis and elevation of his serum creatinine to 2.5 mg/dL. What is the most likely explanation for these findings?
Correct answer
C
Rationale
The correct answer is C) Retroperitoneal fibrosis. In this scenario, the patient's bilateral hydronephrosis and elevated serum creatinine are most likely due to retroperitoneal fibrosis caused by the bromocriptine. Retroperitoneal fibrosis is a known adverse effect of bromocriptine, a central nervous system stimulant used in Parkinson's disease. This condition results from the development of fibrous tissue in the retroperitoneal space, leading to compression of nearby structures, including the ureters, causing hydronephrosis and renal impairment.
Option A) Drug toxicity is not the best choice because it does not specifically address the mechanism of action leading to the renal findings in this case. Renal artery stenosis (Option B) and renal vein thrombosis (Option D) are less likely as they typically present with different clinical features and are not commonly associated with bromocriptine use in Parkinson's disease.
Educationally, understanding the potential side effects and adverse reactions of medications used in neurological conditions like Parkinson's disease is crucial for healthcare professionals. This case highlights the importance of monitoring patients for rare but serious complications associated with central nervous system stimulants, ensuring early detection and management to prevent significant harm.
Option A) Drug toxicity is not the best choice because it does not specifically address the mechanism of action leading to the renal findings in this case. Renal artery stenosis (Option B) and renal vein thrombosis (Option D) are less likely as they typically present with different clinical features and are not commonly associated with bromocriptine use in Parkinson's disease.
Educationally, understanding the potential side effects and adverse reactions of medications used in neurological conditions like Parkinson's disease is crucial for healthcare professionals. This case highlights the importance of monitoring patients for rare but serious complications associated with central nervous system stimulants, ensuring early detection and management to prevent significant harm.